SCHEDULE 13D/A: HiTron Systems Inc. Becomes Majority Shareholder of Exicure, Inc. Following $8.7 Million Investment and Board Appointments
Ownership Disclosure Amendment
HiTron Systems Inc. has completed its second stock purchase in Exicure, Inc., increasing its beneficial ownership to 52.8% and appointing a majority of the Issuer's board members, including its new CEO and CFO.
Summary
- HiTron Systems Inc. completed its Second Stock Purchase of Exicure, Inc. on December 26, 2024.
- This involved purchasing an additional 2,900,000 shares of common stock at $3.00 per share, totaling $8,700,000.
- The purchase was funded through the issuance of Convertible Bonds by HiTron.
- Following this transaction, HiTron Systems Inc. beneficially owns 3,333,333 shares, representing approximately 52.8% of Exicure, Inc.'s outstanding common stock.
- The closing of the Second Stock Purchase was contingent on approval from Exicure's stockholders and Korean Regulatory Approval, both of which were obtained.
- Proceeds from the Initial Stock Purchase were used by Exicure to acquire GPCR Therapeutics USA, Inc., a transaction completed on January 22, 2025.
- Proceeds from the Second Stock Purchase are designated for Exicure's general corporate purposes and business development.
Sentiment
Score: 7
Explanation: The document indicates a significant investment and a change of control, providing capital to Exicure and potentially new strategic direction. The completion of the transaction and the appointment of new leadership are positive steps for the Issuer's stability and future. The lock-up period for HiTron also indicates commitment.
Positives
- Exicure, Inc. received $8,700,000 in funding from the Second Stock Purchase, earmarked for general corporate purposes and business development.
- The Initial Stock Purchase proceeds were successfully used to acquire GPCR Therapeutics USA, Inc., a strategic acquisition completed on January 22, 2025.
- HiTron Systems Inc. has secured a majority ownership stake (52.8%) in Exicure, Inc., providing significant influence over the company's strategic direction.
- New management and board members nominated by HiTron, including Andy Yoo as CEO and President, and Seung Ik Baik as CFO and Secretary, are now in place, potentially bringing new leadership and strategic vision.
Risks
- HiTron Systems Inc. is subject to a 90-day lock-up period with respect to the shares acquired in both the Initial and Second Stock Purchases, limiting immediate liquidity.
- The Reporting Person reserves the right to change its intentions regarding its investment, including increasing or disposing of holdings, which could introduce future uncertainty for other shareholders.
Future Outlook
The Reporting Person acquired the shares for investment purposes and may influence or determine votes on significant matters. Proceeds from the Second Stock Purchase are intended for general corporate purposes and business development. The Reporting Person reserves the right to evaluate Exicure's financial condition and prospects on an ongoing basis and may increase or dispose of its holdings in the future, subject to a 90-day lock-up period. Discussions with management and the board regarding the Issuer's business and financial condition are also anticipated.
Management Comments
- "The Shares reported on this Statement were acquired for investment purposes."
- "The Reporting Person may have the ability, as a result of its holding the Shares, to influence or determine the vote with respect to significant matters involving the Issuer."
- "The Reporting Person expects to evaluate on an ongoing basis the Issuer's financial condition and prospects and its interests in, and intentions with respect to, the Issuer and its investments in the securities of the Issuer."
Industry Context
This filing indicates a significant strategic investment and change of control within the biotechnology sector. HiTron Systems Inc., a South Korean corporation, has taken a majority stake in Exicure, Inc., a U.S.-based company, and installed its own leadership. This suggests a potential shift in Exicure's strategic direction, possibly aligning with HiTron's broader business objectives or leveraging HiTron's resources and expertise. The use of initial proceeds for an acquisition (GPCR Therapeutics USA, Inc.) and subsequent proceeds for general corporate purposes and business development points towards a strategy of growth and integration under new ownership.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer and President | NA | Andy Yoo | 2024-12-17 | Appointed by Issuer Board following stockholder approval of Second Stock Purchase, nominated by Reporting Person. |
| Chief Financial Officer and Secretary | NA | Seung Ik Baik | 2024-12-17 | Appointed by Issuer Board following stockholder approval of Second Stock Purchase, nominated by Reporting Person. |
| Chief Restructuring Officer | NA | Andy Yoo | 2024-11-21 | Appointed by Issuer Board pursuant to the Initial Purchase Agreement, nominated by Reporting Person. |
| Board Member | NA | Andy Yoo | 2024-11-21 | Appointed by Issuer Board pursuant to the Initial Purchase Agreement, nominated by Reporting Person. |
| Board Member | NA | Seung Ik Baik | 2024-11-21 | Appointed by Issuer Board pursuant to the Initial Purchase Agreement, nominated by Reporting Person. |
| Board Member | NA | Ho Jung John | 2024-12-17 | Appointed by Issuer Board, nominated by Reporting Person, resulting in a majority of the board being HiTron nominees. |
| Board Member | NA | Chang Keun Choi | 2024-12-17 | Appointed by Issuer Board, nominated by Reporting Person, resulting in a majority of the board being HiTron nominees. |
| Board Member | NA | Sangwook Song | 2024-12-17 | Appointed by Issuer Board, nominated by Reporting Person, resulting in a majority of the board being HiTron nominees. |
| Board Member | NA | Minwoo Kang | 2024-12-17 | Appointed by Issuer Board, nominated by Reporting Person, resulting in a majority of the board being HiTron nominees. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition Change | A majority of Exicure, Inc.'s Board of Directors is now composed of nominees from HiTron Systems Inc., following the appointment of Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang. | 2024-12-17 | Significantly increases HiTron's control and influence over Exicure's strategic decisions and corporate direction. |
| Director Nomination Rights | Pursuant to the Second Purchase Agreement, HiTron Systems Inc. has the right to nominate a number of directors substantially equivalent to its proportional equity ownership of Exicure's common stock. | 2024-11-13 | Ensures HiTron's continued proportional representation and influence on the board as its ownership stake evolves. |
Related Party Transactions
- The appointments of Andy Yoo (CEO of HiTron) and Seung Ik Baik (Chief Strategic Officer at YooSoo Group, an affiliate of HiTron) to Exicure's board and executive management positions (CEO, President, CFO, Secretary, Chief Restructuring Officer) constitute related party transactions as they are representatives of the Reporting Person or its affiliates.
- The nomination and appointment of additional board members (Ho Jung John, Chang Keun Choi, Sangwook Song, Minwoo Kang) by HiTron, resulting in a majority HiTron-nominated board, also represent related party influence.
Stakeholder Impact
- Shareholders: Existing shareholders will experience a significant dilution of control as HiTron Systems Inc. now holds a majority stake (52.8%). The new capital infusion and strategic direction under HiTron's leadership could impact future share value, positively or negatively depending on performance.
- Employees: New management (CEO, President, CFO, Secretary, Chief Restructuring Officer) from HiTron's side may lead to changes in corporate culture, operational strategies, and potentially organizational structure.
- Customers/Suppliers: The use of proceeds for general corporate purposes and business development, along with the acquisition of GPCR Therapeutics USA, Inc., suggests potential expansion or shifts in product/service offerings, which could affect customer and supplier relationships.
- Creditors: The funding through Convertible Bonds by HiTron to finance the purchase could indirectly affect Exicure's capital structure and financial health, potentially impacting creditors depending on the terms of the bonds and Exicure's overall financial performance.
Next Steps
- Exicure, Inc. will use the proceeds from the Second Stock Purchase for general corporate purposes and business development.
- HiTron Systems Inc. will evaluate Exicure's financial condition and prospects on an ongoing basis.
- HiTron Systems Inc. reserves the right to increase or dispose of its holdings in Exicure, Inc. in the future, subject to lock-up restrictions.
- HiTron Systems Inc. may engage in discussions with Exicure's management and board regarding the Issuer's business and financial condition.
Key Dates
| Date | Description |
|---|---|
| 2024-11-13 | Date HiTron Systems Inc. entered into the Second Common Stock Purchase Agreement with Exicure, Inc. |
| 2024-11-21 | Date Andy Yoo and Seung Ik Baik were appointed to the Issuer Board, and Andy Yoo was appointed Chief Restructuring Officer, pursuant to the Initial Purchase Agreement. |
| 2024-12-17 | Date Andy Yoo was appointed Chief Executive Officer and President of Exicure, Inc., and Seung Ik Baik was appointed Chief Financial Officer and Secretary of the Company. |
| 2024-12-17 | Date Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang were appointed to the Issuer Board, resulting in a majority of the board being HiTron nominees. |
| 2024-12-26 | Date of event requiring filing of this statement; completion of the Second Stock Purchase by HiTron Systems Inc. after receiving stockholder and Korean Regulatory Approval. |
| 2025-01-22 | Date Exicure, Inc. announced the completion of the acquisition of GPCR Therapeutics USA, Inc., funded by the Initial Stock Purchase proceeds. |
| 2025-03-12 | Date Exicure, Inc. reported 6,317,771 shares of Common Stock outstanding in its Annual Report on Form 10-K. |
| 2025-03-18 | Date Exicure, Inc. filed its Annual Report on Form 10-K. |
| 2025-03-26 | Date of signature for this Schedule 13D Amendment No. 1. |
Recommendation
holdKeywords
Exicure Inc., HiTron Systems Inc., Schedule 13D, Beneficial Ownership, Stock Purchase, Corporate Governance, Management Change, Biotechnology Investment, Majority Shareholder, SEC Filing, GPCR Therapeutics USA Inc., Convertible Bonds
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.